FDA approves BridgeBio’s Attruby for ATTR-CM treatment
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
New research labs and process development services to enable next generation therapeutics
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
The product will be manufactured at Lupin’s Somerset facility in the US
Subscribe To Our Newsletter & Stay Updated